Experienced in Chondrosarcoma

Dr. Muhammad K. Riaz

Hematology Oncology | Hematology | Oncology
St Elizabeth Medical Center, Inc
85 N Grand Ave, 
Fort Thomas, KY 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Chondrosarcoma
St Elizabeth Medical Center, Inc
85 N Grand Ave, 
Fort Thomas, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Muhammad Riaz is a Hematologist Oncology specialist and a Hematologist in Fort Thomas, Kentucky. Dr. Riaz is rated as an Experienced provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Riaz is currently accepting new patients.

His clinical research consists of co-authoring 141 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chondrosarcoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
St Elizabeth Florence
Highland District Hospital
St Elizabeth Edgewood
St Elizabeth Ft Thomas
St Elizabeth Grant
Languages Spoken
English
Punjabi
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

ST ELIZABETH MEDICAL CENTER, INC
85 N Grand Ave, Fort Thomas, KY 41075

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
Enrollment Status: Recruiting
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: TAB004, Toripalimab
Study Phase: Phase 1
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: November 25, 2025
Intervention Type: Drug
Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel
Study Phase: Phase 1
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Efatutazone, Paclitaxel
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

141 Total Publications

3D bioprinting of cell-laden constructs: Technologies, bioink design, and biomedical applications.
3D bioprinting of cell-laden constructs: Technologies, bioink design, and biomedical applications.
Journal: Biomedical materials (Bristol, England)
Published: December 02, 2025
Similar Doctors
Experienced in Chondrosarcoma
Dr. Priya G. Jain
Oncology | Hematology Oncology | Hematology
Experienced in Chondrosarcoma
Dr. Priya G. Jain
Oncology | Hematology Oncology | Hematology

Kettering Independent Medical Group Inc

3535 Southern Blvd, Fl 4, 
Kettering, OH 
 (45.3 miles away)
937-395-8251
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients

Priya Jain is an Oncologist and a Hematologist Oncology provider in Kettering, Ohio. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Breast Cancer. Dr. Jain is currently accepting new patients.

Experienced in Chondrosarcoma
Dr. John C. Morris
Oncology
Experienced in Chondrosarcoma
Dr. John C. Morris
Oncology
234 Goodman St, Barrett Center, 
Cincinnati, OH 
 (4.5 miles away)
513-584-6928
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Morris is an Oncologist in Cincinnati, Ohio. Dr. Morris is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Thyroidectomy. Dr. Morris is currently accepting new patients.

Bryan P. Schneider
Experienced in Chondrosarcoma
Dr. Bryan P. Schneider
Hematology Oncology | Oncology | Hematology
Experienced in Chondrosarcoma
Dr. Bryan P. Schneider
Hematology Oncology | Oncology | Hematology

Cutting Edge Physical Therapy Limited Partnership

2390 National Rd W, 
Richmond, IN 
 (57.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bryan Schneider is a Hematologist Oncology specialist and an Oncologist in Richmond, Indiana. Dr. Schneider is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Breast Cancer, Thymic Epithelial Tumor, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. Dr. Schneider is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Riaz's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 24 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile